CN112135605A - 丹曲林制剂及其使用方法 - Google Patents

丹曲林制剂及其使用方法 Download PDF

Info

Publication number
CN112135605A
CN112135605A CN201980033640.3A CN201980033640A CN112135605A CN 112135605 A CN112135605 A CN 112135605A CN 201980033640 A CN201980033640 A CN 201980033640A CN 112135605 A CN112135605 A CN 112135605A
Authority
CN
China
Prior art keywords
dantrolene
pharmaceutical composition
pharmaceutically acceptable
carrier
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980033640.3A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·韦斯科特
吉尔·科兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of CN112135605A publication Critical patent/CN112135605A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980033640.3A 2018-05-21 2019-05-21 丹曲林制剂及其使用方法 Pending CN112135605A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862674394P 2018-05-21 2018-05-21
US62/674,394 2018-05-21
PCT/US2019/033260 WO2019226621A1 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Publications (1)

Publication Number Publication Date
CN112135605A true CN112135605A (zh) 2020-12-25

Family

ID=66821419

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033640.3A Pending CN112135605A (zh) 2018-05-21 2019-05-21 丹曲林制剂及其使用方法

Country Status (15)

Country Link
US (1) US20210236467A1 (https=)
EP (1) EP3796889A1 (https=)
JP (2) JP7762489B2 (https=)
KR (1) KR20210011961A (https=)
CN (1) CN112135605A (https=)
AU (1) AU2019272577B2 (https=)
BR (1) BR112020023012A2 (https=)
CA (1) CA3101093A1 (https=)
IL (1) IL278575B1 (https=)
MA (1) MA52707A (https=)
MX (2) MX2020012464A (https=)
SG (1) SG11202011121UA (https=)
UA (1) UA127661C2 (https=)
WO (1) WO2019226621A1 (https=)
ZA (1) ZA202006986B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英（江苏）药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143677A1 (en) * 2001-06-23 2017-05-25 Lyotropic Therapeutics, Inc. Treatment using dantrolene

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1361092A (en) 1992-03-10 1993-10-05 Kyukyu Pharmaceutical Co., Ltd. Pharmaceutical preparation for percutaneous administration
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143677A1 (en) * 2001-06-23 2017-05-25 Lyotropic Therapeutics, Inc. Treatment using dantrolene

Also Published As

Publication number Publication date
AU2019272577B2 (en) 2024-08-08
MA52707A (fr) 2021-03-31
JP2021524855A (ja) 2021-09-16
ZA202006986B (en) 2024-04-24
MX2025002392A (es) 2025-04-02
IL278575A (https=) 2021-01-31
IL278575B1 (en) 2026-03-01
UA127661C2 (uk) 2023-11-22
JP2024023270A (ja) 2024-02-21
CA3101093A1 (en) 2019-11-28
SG11202011121UA (en) 2020-12-30
AU2019272577A1 (en) 2020-11-26
BR112020023012A2 (pt) 2021-02-02
KR20210011961A (ko) 2021-02-02
JP7762489B2 (ja) 2025-10-30
MX2020012464A (es) 2021-02-09
EP3796889A1 (en) 2021-03-31
WO2019226621A1 (en) 2019-11-28
US20210236467A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
CN110430900B (zh) 包含赛乐西帕的药物组合物
US8476320B2 (en) Formulations for parenteral administration of amino-substituted (E)-2, 6-dialkoxystyryl 4-substituted benzylsulfones
EP3630061B1 (en) Precipitation resistant small molecule drug formulations
CN114555124A (zh) 药物共晶盐制剂
US20250073170A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
EP2666463A1 (en) Stabilized liquid composition comprising pemetrexed
HK1221407A1 (en) Polyethylene glycol-containing composition
US12564619B2 (en) Stable formulations of recombinant proteins
CN112135605A (zh) 丹曲林制剂及其使用方法
US8063109B2 (en) Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones
US8178489B2 (en) Formulation for aviptadil
US20230263900A1 (en) Dendrimer-drug conjugate
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
US12396987B2 (en) Pharmaceutical composition with excellent storage stability
RU2809143C2 (ru) Композиции дантролена и способы их применения
US20250064758A1 (en) Antivirals targeting phosphatidic acid phosphatase (pap)
WO2025247892A1 (en) Intravesical compositions
CN108289844A (zh) 包含非核苷逆转录酶抑制剂和聚（丙交酯-共-乙交酯）的注射溶液
WO2025165852A1 (en) Liquid formulations of lurbinectedin
WO2026090615A1 (en) Polyoxazoline micellar pharmaceutical compositions
US20240180935A1 (en) Solution formulation of cyclophosphamide
CN121731300A (zh) 非胃肠道给药途径的普拉格雷制剂和应用
HK40098449A (zh) 抗沉淀的小分子药物制剂
HK1109088B (en) Solubilization preparation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination